Ocular Therapeutix, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.21 | -$0.17 | -$0.19 |
| Q2 2024 | 2 | -$0.25 | -$0.20 | -$0.22 |
| Q3 2024 | 3 | -$0.27 | -$0.22 | -$0.24 |
| Q4 2024 | 5 | -$0.30 | -$0.15 | -$0.25 |
| Q1 2025 | 3 | -$0.27 | -$0.25 | -$0.26 |
| Q2 2025 | 2 | -$0.30 | -$0.24 | -$0.27 |
| Q3 2025 | 2 | -$0.30 | -$0.24 | -$0.27 |
| Q4 2025 | 2 | -$0.32 | -$0.26 | -$0.29 |
| Q1 2026 | 1 | -$0.37 | -$0.30 | -$0.33 |
| Q2 2026 | 1 | -$0.37 | -$0.30 | -$0.33 |
| Q3 2026 | 1 | -$0.37 | -$0.30 | -$0.33 |
| Q4 2026 | 1 | -$0.38 | -$0.31 | -$0.34 |
Ocular Therapeutix, Inc. Earnings Date And Information
Ocular Therapeutix, Inc. last posted its earnings results on Thursday, November 14th, 2024. The company reported $-0.26 earnings per share for the quarter, missing analysts' consensus estimates of $-0.23 by $0.03. The company had revenue of 15.43 M for the quarter and had revenue of 58.44 M for the year. Ocular Therapeutix, Inc. has generated $-1 earnings per share over the last year ($-1.02 diluted earnings per share) and currently has a price-to-earnings ratio of -8.16. Ocular Therapeutix, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based on prior year's report dates.
Ocular Therapeutix, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$0.23 | -$0.22 | 0.01 | $17.13 M | $15.43 M |
| 08/07/2024 | Q2 2024 | -$0.22 | -$0.26 | -0.04 | $15.85 M | $16.44 M |
| 05/07/2024 | Q1 2024 | -$0.18 | -$0.49 | -0.31 | $14.72 M | |
| 03/11/2024 | Q4 2023 | -$0.28 | -$0.35 | -0.07 | $14.80 M | |
| 11/07/2023 | Q3 2023 | -$0.27 | -$0.01 | 0.26 | $15.23 M | $14.95 M |
| 08/07/2023 | Q2 2023 | -$0.29 | -$0.26 | 0.03 | $14.62 M | $15.19 M |
| 05/08/2023 | Q1 2023 | -$0.27 | -$0.47 | -0.2 | $13.37 M | |
| 03/06/2023 | Q4 2022 | -$0.25 | -$0.15 | 0.1 | $14.08 M | |
| 11/07/2022 | Q3 2022 | -$0.23 | -$0.35 | -0.12 | $14.27 M | $11.97 M |
| 08/08/2022 | Q2 2022 | -$0.23 | -$0.21 | 0.02 | $14.25 M | $12.27 M |
| 05/09/2022 | Q1 2022 | -$0.25 | -$0.09 | 0.16 | $13.19 M | |
| 02/28/2022 | Q4 2021 | -$0.23 | -$0.07 | 0.16 | $12.31 M | |
| 11/08/2021 | Q3 2021 | -$0.26 | $0.03 | 0.29 | $12.45 M | $12.15 M |
| 08/09/2021 | Q2 2021 | -$0.20 | -$0.11 | 0.09 | $10.83 M | $11.72 M |
| 05/05/2021 | Q1 2021 | -$0.20 | $0.04 | 0.24 | $7.34 M | |
| 03/11/2021 | Q4 2020 | -$0.18 | -$1.21 | -1.03 | $7.35 M | |
| 11/05/2020 | Q3 2020 | -$0.23 | -$0.19 | 0.04 | $5.50 M | $5.88 M |
| 08/07/2020 | Q2 2020 | -$0.32 | -$0.64 | -0.32 | $1.50 M | $1.57 M |
| 05/08/2020 | Q1 2020 | -$0.40 | -$0.41 | -0.01 | $2.61 M | |
| 03/12/2020 | Q4 2019 | -$0.42 | -$0.54 | -0.12 | $2.26 M |
Ocular Therapeutix, Inc. Earnings: Frequently Asked Questions
-
When is Ocular Therapeutix, Inc.'s earnings date?
Ocular Therapeutix, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based off last year's report dates.
-
How can I listen to Ocular Therapeutix, Inc.'s earnings conference call?
The conference call for Ocular Therapeutix, Inc.'s latest earnings report can be listened to online.
-
How can I read Ocular Therapeutix, Inc.'s conference call transcript?
The conference call transcript for Ocular Therapeutix, Inc.'s latest earnings report can be read online.
-
How much revenue does Ocular Therapeutix, Inc. generate each year?
Ocular Therapeutix, Inc. (:OCUL) has a recorded annual revenue of $58.44 M.
-
How much profit does Ocular Therapeutix, Inc. generate each year?
Ocular Therapeutix, Inc. (:OCUL) has a recorded net income of $58.44 M. Ocular Therapeutix, Inc. has generated $-1.09 earnings per share over the last four quarters.
-
What is Ocular Therapeutix, Inc.'s price-to-earnings ratio?
Ocular Therapeutix, Inc. (:OCUL) has a price-to-earnings ratio of -8.16 and price/earnings-to-growth ratio is 0.43.
